Indutrade AB (publ) (STO:INDT)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 74.39B |
| Revenue (ttm) | 32.26B |
| Net Income (ttm) | 2.54B |
| Shares Out | 364.32M |
| EPS (ttm) | 6.96 |
| PE Ratio | 29.34 |
| Forward PE | 24.46 |
| Dividend | 3.10 (1.52%) |
| Ex-Dividend Date | Apr 2, 2026 |
| Volume | 892,999 |
| Average Volume | 483,645 |
| Open | 204.80 |
| Previous Close | 204.60 |
| Day's Range | 204.00 - 210.60 |
| 52-Week Range | 194.00 - 280.80 |
| Beta | 1.28 |
| RSI | 37.04 |
| Earnings Date | Apr 24, 2026 |
About Indutrade AB
Indutrade AB (publ) manufactures, develops, and sells components, systems, and services to various industries worldwide. It operates through five segments: Industrial & Engineering, Infrastructure & Construction, Life Science, Process, Energy & Water, and Technology & Systems Solutions. The company offers industrial equipment, tools, filters, hydraulics, fasteners, and chemical technology for general engineering and automotive industries; and flow technology products, including valves, pipes and pipe systems, and pumps, as well as measurement t... [Read more]
Financial Performance
In 2025, Indutrade AB's revenue was 32.23 billion, a decrease of -0.97% compared to the previous year's 32.54 billion. Earnings were 2.56 billion, a decrease of -6.88%.
Financial StatementsNews
Indutrade AB (IDTRY) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ...
Indutrade AB (IDTRY) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Acquisitions
Q1 2026 Indutrade AB Earnings Call Transcript
Q1 2026 Indutrade AB Earnings Call Transcript
Indutrade AB Earnings Call Transcript: Q1 2026
Order intake grew 1% organically year-over-year, with strong performance in MedTech, pharma, and energy, while net sales were flat due to currency headwinds. EBITDA margin held at 13.3%, and the order backlog is expected to drive improved sales in Q2 and Q3.
Indutrade AB Earnings Call Transcript: Q4 2025
2025 featured improved order intake and strong cash flow despite market uncertainty and one-off project costs. Acquisitions accelerated, margins remained robust on an adjusted basis, and the outlook is positive with a focus on organic and acquisition-driven growth.
Indutrade AB Transcript: CMD 2025
Reconfirmed financial targets and a decentralized, growth-focused strategy, with a new organizational structure to double the group's size. Disciplined acquisition approach, enhanced internal lead generation, and strong cash flow support both organic and M&A-driven expansion.
Indutrade AB Earnings Call Transcript: Q3 2025
Organic order intake rose 3% year-over-year, while net sales declined 2% due to currency and tough comparables. EBITDA margin remained strong at 14.6%, with robust cash flow and improved net debt ratios. Acquisition activity accelerated, supporting long-term growth.
Indutrade AB Earnings Call Transcript: Q2 2025
Order intake was stable with a positive book-to-bill ratio, but net sales and profit declined due to tough comparisons and market headwinds. Cost adaptation and a strong acquisition pipeline support a positive outlook for H2.
Indutrade AB Earnings Call Transcript: Q1 2025
Order intake and sales grew, driven by acquisitions and strong demand in pharma, process, and energy. EBITDA and gross margin reached record Q1 levels, with robust cash flow and low leverage. Market volatility and tariffs pose risks, but outlook for margin recovery and acquisitions remains positive.
Indutrade AB Earnings Call Transcript: Q4 2024
Solid 2024 results with 2% growth in orders and sales, stable margins, and record cash flow. Acquisitions and sustainability progress strengthened the platform, while Life Science and Process, Energy and Water led segment growth. Market uncertainty persists, but outlook is positive.
Indutrade AB Earnings Call Transcript: Q3 2024
Order intake and sales grew modestly, with strong performance in Life Science and Process, Energy & Water, while infrastructure and construction remained weak. Thirteen acquisitions were completed, and the financial position remains solid with strong cash flow and improved debt ratios.
Indutrade AB Earnings Call Transcript: Q2 2024
Order intake and net sales grew 6% and 5% year-over-year, with strong EBITDA margin and record acquisition pace. Robust demand in MedTech, pharma, and process industries offset weaker infrastructure and construction, while cost management and cash flow remained solid.